您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 瑞士药房
产地国家: 瑞士
所属类别: 抗微生物药物->抗病毒药物
处方药:处方药
包装规格: 2500单位/50毫升/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
瑞士Biotest
生产厂家英文名:
Biotest Switzerland
该药品相关信息网址1:
http://www.paviour.org/cytotect.htm
该药品相关信息网址2:
http://www.margalit-ltd.co.il/megalotect.php
原产地英文商品名:
CYTOTECT 2500IU/50ML/VIAL
原产地英文药品名:
HUMAN CYTOMEGALOVIRUS IMMUNOGLOBULIN
中文参考商品译名:
施多特 2500单位/50毫升/瓶
中文参考药品译名:
人类巨细胞病毒免疫球蛋白
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
CMV
临床试验期:
完成
中文适应病症参考翻译1:
巨细胞病毒
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201111817470625.PDF,201111817470111.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文CYTOTECT处方资料(仅供参考)

商品名:CYTOTECT BIOTEST 50ML/VIAL

药品名称:人类巨细胞病毒免疫球蛋白/cytomegalovirus immunoglobulin, human

药理作用:本品系从人血浆制备的含有高水平抗巨细胞病毒(CMV)特异性抗体的免疫球蛋白。

适应症:用于CMV感染的被动免疫,尤其是预防性或治疗性地应用于接受移植的患者。有静注和肌注用制剂,迄今本品在肾、心脏、骨髓及肝脏移植患者中对CMV感染的预防和治疗效果已进行了初步评估,但确切疗效尚在进一步研究评估中。

不良反应:类同一般免疫球蛋白。

Cytotect Biotest
Human immunoglobulin anti- cytomegalovirus (50 I. U. / ml)

Composition: 1ml solution contains: protein 100 mg, of which human immunoglobulin makes up at least 95% Antibody content against cytomegalovirus 50 I.U. Further constituents : Sodium chloride, water for injections.
 
Indications: Prophylaxis of clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients.
 
Contra-Indications: Megalotect® is contra-indicated in patients who are intolerant to human immunoglobulin especially in very rare cases of IgA deficiency, when the patient has antibodies against IgA. Pregnancy and lactation : The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Long lasting clinical experience with immunoglobulins does indicate that no harmful effects on the course of pregnancy, on the foetus and the neonate are to be expected.
 
Immunoglobulins are excreted into the milk and may contribute to the transfer of protective antibodies to the neonate.
 
Special precautions for use: Certain severe adverse drug reactions may be related to the rate of infusion. The recommended infusion rate given under "Method of administration" must be closely followed and patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Patients should be observed for at least 20 minutes after administration. Effects on ability to drive and use machines: There are no indications that Megalotect® may impair the ability to drive and use machines.
 
Dosage instructions and duration of application: As a rule doses containing 50 units (PEI) Per Kg Body Weight, Which Corresponds To 1 ml, should be administered. Administration should be initiated on the day of transplantation or the day prior to this (bone marrow transplantation). A total of at least 6 doses at 2 to 3 weeks' intervals should be given.
 
Interactions with other medicinal products: Live attenuated virus vaccines: immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps, and varicella. After injection of immunoglobulins the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.
 
Method of administration: Megalotect® is intended for intravenous use. During the infusion, the rate of 20 drops per minute (corresponding to 1 ml per minute) must not be exceeded. Megalotect® should be inspected visually for particulate matter and discoloration prior to administration. Do not use solutions which are cloudy or which have deposits. Megalotect® should be brought to room or body temperature before administration.
 
Special precautions for storage: Megalotect® has to be stored at + 2 ºC TO +8 ºC Protected From Light. Do not freeze. Megalotect® should not be used after the expiry date indicated on the label. Any unused solution must be discarded because of bacterial contamination risk.
 
Presentations: Ampoules with 5 ml, 10 ml and 20 ml, infusion bottle with 50 ml. For additional information see package insert.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201111817470625.PDF,201111817470111.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2012-3-13
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com